<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16F4B5D5-CAB9-4758-ABBB-E469E584F214"><gtr:id>16F4B5D5-CAB9-4758-ABBB-E469E584F214</gtr:id><gtr:name>Hunter Medical Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16F4B5D5-CAB9-4758-ABBB-E469E584F214"><gtr:id>16F4B5D5-CAB9-4758-ABBB-E469E584F214</gtr:id><gtr:name>Hunter Medical Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6A6BC2D8-CDFF-48E1-ADD7-DDA443526623"><gtr:id>6A6BC2D8-CDFF-48E1-ADD7-DDA443526623</gtr:id><gtr:firstName>Sebastian</gtr:firstName><gtr:otherNames>L</gtr:otherNames><gtr:surname>Johnston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BDFDF6F1-9BA1-486F-9980-D7F98A0BF3E1"><gtr:id>BDFDF6F1-9BA1-486F-9980-D7F98A0BF3E1</gtr:id><gtr:firstName>Nathan</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Bartlett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1EEF2886-0BDB-4D93-BEFD-16C71342AE0F"><gtr:id>1EEF2886-0BDB-4D93-BEFD-16C71342AE0F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>McKenzie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100168"><gtr:id>63932EF6-DAD8-4DDC-B35B-8848329C14E7</gtr:id><gtr:title>Defining the importance of IL-25 in rhinovirus-induced asthma exacerbations</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100168</gtr:grantReference><gtr:abstractText>Asthma is the most common respiratory disease and has increased over recent decades, such that in many European countries ~30% of children now report wheeze in the last year. Rhinovirus (RV) infection is the dominant individual cause of acute exacerbations in both adults and children. Despite the enormous associated illness current therapies are ineffective and the mechanisms of RV induced asthma exacerbations are poorly understood. Asthmatics produce a molecule in their lungs, IL-25, that is potentially important in causing exacerbations. We aim to understand the role of IL-25 in immune responses to RV infections and asthma exacerbations and determine if this molecule is a suitable candidate for development of better treatments. To determine if IL-25 is associated with immune responses that regulate exacerbation severity we have developed a human experimental RV-induced asthma exacerbation model. Clinical samples from this study will enable us to investigate the association between IL-25 expression and host responses that cause asthma exacerbations. To support human studies we have recently developed the world?s first mouse models of rhinovirus infection and exacerbation of asthma demonstrating numerous asthma related outcomes exacerbated by infection in the mouse. These mouse models of rhinovirus infection and asthma exacerbation will enable investigation within the mammalian airway to establish a causal role in disease for IL-25. The objective of this proposal is therefore to utilize human and models of rhinovirus-induced asthma exacerbation to define a role for IL-25 in the immune response and airways disease, research fundamental to the development of better treatments for asthma exacerbations.</gtr:abstractText><gtr:technicalSummary>We hypothesise that rhinovirus infection induces IL-25, which in atopic asthmatics, amplifies Th2 responses in the airways causing asthma exacerbations. To test this hypothesis we will employ two state of the art in vivo models. First a human model of experimental rhinovirus infection in atopic asthma and healthy subjects. This will enable us to assess RV-induced IL-25 expression during asthma exacerbations and also to compare production in asthma and healthy subjects. Furthermore we will be able correlate IL-25 production with Th2 responses, mucus production, clinical illness severity and virus load. IL-25 protein will be measured in airway lining fluid by MSD and in bronchial biopsies by immunohistochemistry. IL-25 gene expression analysis of bronchial epithelial cells taken during bronchoscopy will also be undertaken. This study will be the first to assess the role of IL-25 in asthma exacerbations and be an important addition to the few published human studies. We also plan to use mouse models of RV infection and asthma exacerbation in which we can manipulate IL-25 activity and monitor Th2 immune responses and asthma-relevant markers of airways disease. Initially we will study rhinovirus infection (minor and major group) and IL-25 expression (gene and protein) in the lung using mouse infection models previously developed by us. Next we will use a model of rhinovirus induced exacerbation of allergic airways inflammation also previously developed by us. This will enable us to investigate the effect of RV infection and allergen challenge on IL-25 expression. Using a neutralising mAb we will determine the role of IL-25 in mediating AHR, Th2 immunity and airways disease in the exacerbation of allergic airways disease model. Administering the IL-25 neutralising mAb to an IL-13- reporter mouse will enable evaluation of the role of IL-25 on IL-13 expression. If IL-25 expression is induced and related to disease outcomes in the human model, AND causally related to Th2 mediated disease outcomes in the mouse in vivo model this cytokine will be a good target to direct development of novel treatments for RV-induced asthma exacerbations.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>274027</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hunter Medical Research Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Mattes Foster, CARD, HMRI</gtr:description><gtr:id>9C0365CE-FE6E-4A20-9196-B0DCE57D8BDA</gtr:id><gtr:impact>Publications
PMID:23334847</gtr:impact><gtr:outcomeId>NjsePW5rwe6-1</gtr:outcomeId><gtr:partnerContribution>Set up mouse model, conducted research and prepared manuscript</gtr:partnerContribution><gtr:piContribution>Transfer of mouse model of rhinovirus infection and contributed to study design, data interpretation and preparation of manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Antibody mediated blockade of IL-25 receptor</gtr:description><gtr:id>C5EB531D-9325-4B34-80FA-A83D0EE3B0D3</gtr:id><gtr:impact>MRC project grant G1100168 Defining the importance of IL-25 in rhinovirus-induced asthma exacerbations
Publication Beale et al Science TM 2014</gtr:impact><gtr:outcomeId>5462c1fc170057.98693607-1</gtr:outcomeId><gtr:partnerContribution>Supplied IL-25 receptor blocking antibody for use in mouse studies</gtr:partnerContribution><gtr:piContribution>Conducted the mouse studies at Imperial College London</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Ministry of Education of Greece Cooperation Programme THALIS</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Government of Greece</gtr:fundingOrg><gtr:id>CC1B6F21-DF14-4F74-8753-3EA47E1BBF82</gtr:id><gtr:outcomeId>AdxEZLgbma6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The IL-25 receptor blocking monoclonal antibody (anti-IL-25) has been demonstrated to inhibit pulmonary inflammation caused by rhinovirus infection in a mouse asthma model. The antibody is currently developed for use in mouse models. The most recent source of funding MRC project grant G1100168 Defining the importance of IL-25 in rhinovirus-induced asthma exacerbations.</gtr:description><gtr:id>353EF7DB-144F-4180-894E-9E5F9C838934</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>5462c72f9a6915.00429388</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>IL-25 receptor blocking antibody</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/25273095</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4C07BA50-3C8F-4E83-8997-FFE0B8933DB7</gtr:id><gtr:title>Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a60e28f2a1214b4efd1d55a151a8fffd"><gtr:id>a60e28f2a1214b4efd1d55a151a8fffd</gtr:id><gtr:otherNames>Beale J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>546182adaf9823.20798167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAB0BB66-79F0-47B9-9E3E-276754E322B4</gtr:id><gtr:title>Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4eeed7b7d1f03fb9de82b125ee80de2"><gtr:id>d4eeed7b7d1f03fb9de82b125ee80de2</gtr:id><gtr:otherNames>Toussaint M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>5a578d2dc6a585.45019188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D56DEC-50A0-420B-8AC5-512AC48DF98B</gtr:id><gtr:title>Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08cd64da90b2e568366bd01992a71db0"><gtr:id>08cd64da90b2e568366bd01992a71db0</gtr:id><gtr:otherNames>Mahmutovic-Persson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>546182ad5edc85.66866129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7EE6BDC-86AE-4030-853B-D4B96741DC11</gtr:id><gtr:title>Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c5c3cfbf91f9a762e34c2c5d214ec19"><gtr:id>4c5c3cfbf91f9a762e34c2c5d214ec19</gtr:id><gtr:otherNames>McLean GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>pm_13564_24_22742898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8A785DE-E39D-47C0-807F-A9C6C83CB8D1</gtr:id><gtr:title>IL-15 complexes induce NK- and T-cell responses independent of type I IFN signaling during rhinovirus infection.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afaac192e887af5e9947981b04341aa9"><gtr:id>afaac192e887af5e9947981b04341aa9</gtr:id><gtr:otherNames>Jayaraman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>546182ad89e6c3.44033009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C43AC7CE-ACAF-4C5D-BF7D-3ED5FDAA452A</gtr:id><gtr:title>Mouse models of rhinovirus infection and airways disease.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53c40f2caff46206449237c31dd0da82"><gtr:id>53c40f2caff46206449237c31dd0da82</gtr:id><gtr:otherNames>Bartlett NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>978-1-4939-1570-5</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>545a500e510fd5.78305520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>337E1BCA-AD03-4F8D-9133-C78F55CBAB0B</gtr:id><gtr:title>Defining critical roles for NF-?B p65 and type I interferon in innate immunity to rhinovirus.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53c40f2caff46206449237c31dd0da82"><gtr:id>53c40f2caff46206449237c31dd0da82</gtr:id><gtr:otherNames>Bartlett NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>pm_13564_24_23165884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DABD1C6-3119-48D5-AA76-67573FEF3BB6</gtr:id><gtr:title>An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc8ce2c27d2bd615949f3288e844e60"><gtr:id>7cc8ce2c27d2bd615949f3288e844e60</gtr:id><gtr:otherNames>Traub S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>doi_13564_at_1003520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56442F72-FADC-4F36-B189-3874256E4D2A</gtr:id><gtr:title>Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial.</gtr:title><gtr:parentPublicationTitle>JAMA internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5638cdb8eec944bcf9fe079c92dd7fe8"><gtr:id>5638cdb8eec944bcf9fe079c92dd7fe8</gtr:id><gtr:otherNames>Johnston SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6106</gtr:issn><gtr:outcomeId>58c28ac8147d98.42602994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BE4F05A-C34B-4019-9CB8-F7353541A364</gtr:id><gtr:title>The microbiology of asthma.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8603744bac0fd9c512c0c37ca4382a6a"><gtr:id>8603744bac0fd9c512c0c37ca4382a6a</gtr:id><gtr:otherNames>Edwards MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>pm_13564_24_22669219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2844469-0190-4E2F-8EAB-5931F55C3A00</gtr:id><gtr:title>?dT cells suppress inflammation and disease during rhinovirus-induced asthma exacerbations.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a71a1d8508f3e1d35896d73d24e16a82"><gtr:id>a71a1d8508f3e1d35896d73d24e16a82</gtr:id><gtr:otherNames>Glanville N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>doi_13564__mi_2013_3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>501B534C-895D-4C15-A03F-65B054D389AE</gtr:id><gtr:title>Plasmacytoid dendritic cells drive acute asthma exacerbations.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c0066248b60d5f427ed581eaa6f423"><gtr:id>50c0066248b60d5f427ed581eaa6f423</gtr:id><gtr:otherNames>Chairakaki AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a9d1336e293d4.49445446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C94F26B-72FF-4894-8AD9-B4BA30DB23F7</gtr:id><gtr:title>IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f4428e74d7e20f063684d7234777b16"><gtr:id>0f4428e74d7e20f063684d7234777b16</gtr:id><gtr:otherNames>Jackson DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>546182add8fed5.27546360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58E89A3D-84C8-4510-B43B-E9DBE1065921</gtr:id><gtr:title>The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0020ca7ae1fb367a704f750f20801cfa"><gtr:id>0020ca7ae1fb367a704f750f20801cfa</gtr:id><gtr:otherNames>Collison A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>doi_13564_38_nm_3049</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100168</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>